Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 190

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 190
---
. ParentCo will also be exposed to the risk that its partners in strategic investments may encounter financial difficulties that could lead to disruption of investee or partnership activities, or impairment of assets acquired, which could materially adversely affect future reported results of operations and financial condition.

Nasdaq may not agree to list ParentCo’s securities from trading on its exchange, which could limit investors’ ability to make transactions in ParentCo’s securities and subject us to additional trading restrictions.

Iris cannot assure that ParentCo’s securities will be listed on Nasdaq after the Business Combination. In order to continue listing ParentCo’s securities on Nasdaq after the Business Combination, ParentCo must maintain certain financial, distribution and stock price levels. Generally, ParentCo must maintain a minimum amount in stockholders’ equity and a minimum number of holders of ParentCo’s securities. Additionally, in connection with the Business Combination, ParentCo will be required to comply with Nasdaq’s initial listing requirements, which are more rigorous than Nasdaq’s continued listing requirements, in order to maintain the listing of ParentCo’s securities on Nasdaq. Iris cannot assure you that ParentCo will be able to meet those initial listing requirements or obtain all the necessary approvals. Failure to obtain the necessary approvals will result in the failure of the Business Combination to be consummated. If Nasdaq does not agree to list ParentCo’s securities for trading on its exchange and ParentCo is not able to list its securities on another national securities exchange, Iris expects ParentCo’s securities could be quoted on an over-the-counter market. If this were to occur, ParentCo could face significant material adverse consequences, including:

•

a limited availability of market quotations for ParentCo’s securities;

•

reduced liquidity for ParentCo’s securities;

•

a determination that ParentCo’s common stock is a “penny stock” which will require brokers trading in ParentCo’s common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for ParentCo’s securities;

•

a limited amount of news and analyst coverage; and

•

a decreased ability to issue additional securities or obtain additional financing in the future.

The delisting of our securities from Nasdaq may have a material adverse effect on the trading and price of our securities.

On September 6, 2024, our securities were delisted from Nasdaq. The delisting of our securities from Nasdaq may have a material adverse effect on us, including:

•

a limited availability of market quotations for our securities;

•

reduced liquidity of